Abstract A029: Larotrectinib long-term efficacy and safety in pediatric patients with TRK fusion non-primary CNS tumors: Analysis update

Cancer Research 2026

View at publisher
Authors: Leo Mascarenhas, Theodore Willis Laetsch, Birgit Geoerger, Steven G. DuBois, Miranda P. Dierselhuis, Catherine Michelle Albert, Claudia Blattmann, Helen Toledano, Noah C. Federman, Ramamoorthy Nagasubramanian, Alberto S. Pappo, Tanya Carens Watt
+5 more Domnita-Ileana Burcoveanu, Esther A. De La Cuesta, Natascha Neu, Daniel H. Orbach, Yizhuo Zhang
DOI: 10.1158/1538-7445.fusionpositive26-a029
Cited by: 0

Abstract

Abstract Background: NTRK gene fusions are oncogenic drivers across various pediatric and adult tumor types. The prevalence of NTRK gene fusions varies widely, from high (up to 90%) in rare tumors such as infantile fibrosarcoma and secretory carcinoma of the breast to low (

Fields of Study & Subjects

Sarcoma Diagnosis and Treatment Lung Cancer Treatments and Mutations Cancer Genomics and Diagnostics

Publication details

Journal / source
Cancer Research
Volume
86
Issue
1_Supplement
Pages
A029–A029
Publication date
13 January 2026
Language
EN